Literature DB >> 29968184

Model-Based Residual Post-Processing for Residual Model Identification.

Moustafa M A Ibrahim1,2, Rikard Nordgren1, Maria C Kjellsson1, Mats O Karlsson3.   

Abstract

The purpose of this study was to investigate if model-based post-processing of common diagnostics can be used as a diagnostic tool to quantitatively identify model misspecifications and rectifying actions. The main investigated diagnostic is conditional weighted residuals (CWRES). We have selected to showcase this principle with residual unexplained variability (RUV) models, where the new diagnostic tool is used to scan extended RUV models and assess in a fast and robust way whether, and what, extensions are expected to provide a superior description of data. The extended RUV models evaluated were autocorrelated errors, dynamic transform both sides, inter-individual variability on RUV, power error model, t-distributed errors, and time-varying error magnitude. The agreement in improvement in goodness-of-fit between implementing these extended RUV models on the original model and implementing these extended RUV models on CWRES was evaluated in real and simulated data examples. Real data exercise was applied to three other diagnostics: conditional weighted residuals with interaction (CWRESI), individual weighted residuals (IWRES), and normalized prediction distribution errors (NPDE). CWRES modeling typically predicted (i) the nature of model misspecifications, (ii) the magnitude of the expected improvement in fit in terms of difference in objective function value (ΔOFV), and (iii) the parameter estimates associated with the model extension. Alternative metrics (CWRESI, IWRES, and NPDE) also provided valuable information, but with a lower predictive performance of ΔOFV compared to CWRES. This method is a fast and easily automated diagnostic tool for RUV model development/evaluation process; it is already implemented in the software package PsN.

Keywords:  conditional weighted residuals; diagnostics; model evaluation; nonlinear mixed effects models; residual error model

Mesh:

Year:  2018        PMID: 29968184     DOI: 10.1208/s12248-018-0240-7

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  25 in total

1.  Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis.

Authors:  Ulrika Wählby; Alison H Thomson; Peter A Milligan; Mats O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

2.  PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Authors:  Lars Lindbom; Pontus Pihlgren; E Niclas Jonsson; Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2005-09       Impact factor: 5.428

3.  The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion.

Authors:  Hanna E Silber; Maria C Kjellsson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-02-14       Impact factor: 2.745

4.  Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia.

Authors:  L E Friberg; R de Greef; T Kerbusch; M O Karlsson
Journal:  Clin Pharmacol Ther       Date:  2009-04-22       Impact factor: 6.875

5.  Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.

Authors:  Lena E Friberg; Anja Henningsson; Hugo Maas; Laurent Nguyen; Mats O Karlsson
Journal:  J Clin Oncol       Date:  2002-12-15       Impact factor: 44.544

6.  Population pharmacokinetics of ethambutol in South African tuberculosis patients.

Authors:  Siv Jönsson; Alistair Davidse; Justin Wilkins; Jan-Stefan Van der Walt; Ulrika S H Simonsson; Mats O Karlsson; Peter Smith; Helen McIlleron
Journal:  Antimicrob Agents Chemother       Date:  2011-06-20       Impact factor: 5.191

7.  Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke.

Authors:  Siv Jönsson; Yi-Fang Cheng; Charlotte Edenius; Kennedy R Lees; Tomas Odergren; Mats O Karlsson
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

8.  Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial.

Authors:  Björn Hornestam; Markus Jerling; Mats O Karlsson; Peter Held
Journal:  Eur J Clin Pharmacol       Date:  2003-02-19       Impact factor: 2.953

9.  Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods.

Authors:  D R Mould; R N Upton
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-04-17

10.  A strategy for residual error modeling incorporating scedasticity of variance and distribution shape.

Authors:  Anne-Gaëlle Dosne; Martin Bergstrand; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-12-17       Impact factor: 2.745

View more
  3 in total

1.  Development of visual predictive checks accounting for multimodal parameter distributions in mixture models.

Authors:  Usman Arshad; Estelle Chasseloup; Rikard Nordgren; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-04-09       Impact factor: 2.745

2.  Variability Attribution for Automated Model Building.

Authors:  Moustafa M A Ibrahim; Rikard Nordgren; Maria C Kjellsson; Mats O Karlsson
Journal:  AAPS J       Date:  2019-03-08       Impact factor: 4.009

3.  Iberoamerican Pharmacometrics Network Congress 2018 Report: Fostering Modeling and Simulation Approaches for Drug Development and Regulatory and Clinical Applications in Latin America.

Authors:  Manuel Ibarra; Teresa Dalla Costa; Paula Schaiquevich; Rodrigo Cristofoletti; Ignacio Hernández González; Nicte S Fajardo-Robledo; Marcela Aragón Novoa; Marisín Pecchio; Ignacio Cortinez; Iñaki F Trocóniz; Elba M Romero-Tejeda
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-02-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.